BEAMSTART Logo

AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering

Benzinga LogoBenzinga2d ago

AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering - Benzinga

Quick Summary:

The offering consists of 40,000,000 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant, (ii) one (1) Series A Registered Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $0.625 (the "Series A Warrants") and (iii) one (1) Series B Registered Common Warrant to purchase one (1) share of Common Stock per warrant at an exercise price of $0.625 the "Series B Warrants" and together with the Series A Warrants, the "Warrants").

Solely to cover over-allotments, if any, the Company has granted Aegis Capital Corp.("Aegis") a 45-day option to purchase additional shares of Common Stock and/or Warrants of (i) up to 15.0% of the number of shares of Common Stock sold in the offering, (ii) up to 15.0% of the number of Series A Warrants sold in the ...

The number of securities issuable under the Series A Warrants is subject to adjustment as described in more detail in the report on the Company's Current Report on Form 8-K filed with the SEC in connection with the offering (the "8-K").


More Pictures

AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering - Benzinga (Picture 1)

or

Article Details

Author / Journalist: Globe Newswire

Category: InvestingBusiness

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-01-06 @ 14:00:00 (2 days ago)

News Timezone: GMT +8:00

News Source URL: benzinga.com

Language: English

Article Length: 1481 words

Reading Time: 9 minutes read

Sentences: 49 lines

Sentence Length: 31 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Benzinga

News ID: 24941855

View Article Analysis

About Benzinga

Benzinga Logo

Main Topics: InvestingBusiness

Official Website: benzinga.com

Year Established: 2010

Headquarters: United States

News Last Updated: 1 days ago

Coverage Areas: United States

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #54

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering" has 1481 words across 49 sentences, which will take approximately 7 - 13 minutes for the average person to read.

Which news outlet covered this story?

The story "AEON Biopharma, Inc. Announces Pricing of Approximately $20.0 Million Underwritten Public Offering" was covered 2 days ago by Benzinga, a news publisher based in United States.

How trustworthy is 'Benzinga' news outlet?

Benzinga is a fully independent (privately-owned) news outlet established in 2010 that covers mostly investing and business news.

The outlet is headquartered in United States and publishes an average of 0 news stories per day.

It's most recent story was published 1 days ago.

What do people currently think of this news story?

The sentiment for this story is currently Negative, indicating that people regard this as "bad news".

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #24941855
  • URL: https://beamstart.com/news/aeon-biopharma-inc-announces-pricing-1736208369603

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2025 BEAMSTART. All Rights Reserved.